User login
Language
Anonymous's groups in this site
User is not a member of any group.
Your groups across all your sites
User is not a member of any group.
Recent Content
Recent Comments
- USDA faulted for disclosing scant information about bird flu 1 day 23 hours ago
- United Health advancec over $2 billion to hacking victims 1 month 6 days ago
- Charts show how flu, COVID and RSV have spread in the U.S. 1 month 1 week ago
- Congressional funding resources cutbacks likely 2 months 3 weeks ago
Who's online
There is currently 1 user online.
- mike kraft
You are here
ASSOCIATED PRESS by JONATHAN PAYE-LAYLEH Feb. 2, 2015
MONROVIA--A large-scale human trial of two potential Ebola vaccines got under way in Liberia's capital Monday, part of a global effort to prevent a repeat of the epidemic that has now claimed nearly 9,000 lives in West Africa.
The trials in Liberia are taking place after smaller studies determined that the vaccines were safe for human use. By comparing them now with a placebo shot, scientists hope to learn whether they can prevent people from contracting the ghastly virus that has killed some 60 percent of those hospitalized with the disease.
Yet despite the trials' promise, authorities still must combat fear and suspicion that people could become infected by taking part. Each vaccine uses a different virus to carry non-infectious Ebola genetic material into the body and spark an immune response.
Read complete story.
http://abcnews.go.com/Health/wireStory/ebola-vaccine-trial-starts-liberia-28657084
Comments
However. trial stopped on another drug, Chimerix
NEW YORK TIMES by Andrew Pollack Feb. 2, 2015
A clinical trial in Liberia of a drug to treat Ebola has been halted because of a sharp decline in the number of people infected with the virus, and studies in West Africa of other potential treatments are also facing problems finding patients.
The halted trial was testing the antiviral drug brincidofovir at a clinic in Monrovia, Liberia. The developer of the drug, Chimerix, announced late Friday that it would no longer participate in the study.
“Without having enough patients there to make any conclusions, it wasn’t feasible for us to push forward,” Dr. M. Michelle Berrey, chief executive of Chimerix, said in an interview Sunday. She said the company had shipped enough of the drug to Liberia for 140 patients, but that fewer than 10 had been treated since the trial started on Jan. 2.
Read complete story.
http://www.nytimes.com/2015/02/02/business/ebola-drug-trial-is-halted-for-lack-of-patients.html?_r=0